EICHOR
● Completed
Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients
Condition: Non Small Cell Lung Cancer · Advanced Solid Tumor · Sponsor: Institut Bergonié
About this study
Multicenter prospective cohort study aiming to evaluate the detection rate of EGFR gene mutation in patients with advanced NSCLC in a real-word clinical setting, based on liquid biopsy and tissue analyses.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (9)
| Institut de Cancérologie de l'Ouest - Site Paul Papin | Angers, France | — |
| Institut Bergonie | Bordeaux, France | — |
| CHRU Lille | Lille, France | — |
| Hospices Civils de Lyon | Lyon, France | — |
| CHU Nice-Hopital de Cimiel | Nice, France | — |
| Institut Curie | Paris, France | — |
| CHU Poitiers | Poitiers, France | — |
| CHU de Rennes - Hopital Pontchaillou | Rennes, France | — |
| CHU Strasbourg | Strasbourg, France | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04912687